{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.71","value":"69.48"},{"groupId":"OG001","spread":"21.69","value":"68.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"188"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.38","value":"0.91"},{"groupId":"OG001","spread":"15.99","value":"3.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"title":"CFB at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.29","value":"-14.00"},{"groupId":"OG001","spread":"42.15","value":"-4.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"CFB at Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.79","value":"0.35"},{"groupId":"OG001","spread":"17.35","value":"5.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"title":"CFB at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.88","value":"5.71"},{"groupId":"OG001","spread":"22.20","value":"5.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"title":"CFB at End of Induction Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.12","value":"5.19"},{"groupId":"OG001","spread":"18.95","value":"6.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"128"}],"units":"Participants"}],"title":"CFB at Follow-up Month 2"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"14.14","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"CFB at Follow-up Month 4"},{"categories":[{"measurements":[{"comment":"Standard deviation is non-evaluable due to low number of participants.","groupId":"OG000","spread":"NA","value":"10.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"CFB at Follow-up Month 14"}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"188"}],"units":"Participants"}],"description":"EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under \"CFB at Follow-up Month 2\" and \"CFB at Follow-up Month 4\" categories.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEAN","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and \"n\" signified those participants who were evaluable for a specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4 and 14","title":"CFB in EQ-5D Visual Analogue Scale (VAS) Score During Induction Phase","type":"SECONDARY","unitOfMeasure":"units on a scale"}